Company Profile
Tempest Therapeutics Stock Price, News & Analysis
- Ticker:
- TPST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.93 USD (+0.94%)
Close
Last updated: July 27, 2026
19.4M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, TPST closed up 0.94% at $0.9346. No new same-company headline was identified in the current news window.
Company overview
Business overview
Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.
Geographic Base and Sector Classification
Tempest is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The business depends on clinical readouts, partnership potential, and capital discipline while it advances a narrow set of cancer programs. Investors usually watch efficacy, tolerability, and proof that the strategy can survive in a crowded field.
Position Within the Biotechnology Landscape
Tempest occupies a high-volatility oncology niche within biotech. The stock can move quickly on data because the pipeline is narrow and the catalyst schedule matters.
Future catalysts
Near-term attention for Tempest Therapeutics is likely to stay on REDEEM-1 and TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) An.... The current setup is really about Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati.... That is where the next meaningful signal is most likely to come from.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tempest Therapeutics (TPST)?
Tempest Therapeutics (TPST) most recently closed at 0.93 USD, a +0.94% move versus the previous session.
What is the market cap of Tempest Therapeutics (TPST)?
Tempest Therapeutics currently has a market capitalization of 19.4M USD on BioPharmSignal.
What does Tempest Therapeutics do?
Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.
On which exchange is TPST stock listed?
Tempest Therapeutics (TPST) is associated with NASDAQ, United States, Biopharma.
What is REDEEM-1?
Near-term attention for Tempest Therapeutics is likely to stay on REDEEM-1 and TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) An....
Which conditions is Tempest Therapeutics targeting with REDEEM-1?
Tempest Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Tempest Therapeutics describe recent progress with REDEEM-1?
Near-term attention for Tempest Therapeutics is likely to stay on REDEEM-1 and TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) An....
What is TPST-2003?
Near-term attention for Tempest Therapeutics is likely to stay on REDEEM-1 and TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) An....